Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulet Corporation

https://www.insulet.com/

Latest From Insulet Corporation

Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Deals Business Strategies

Analysts Are Bullish On Insulet’s Omnipod 5 For Managing Type 1 Diabetes

A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.

Clinical Trials Commercial

Glooko Raises $30M To Accelerate Commercial Strategy, R&D, Tuck-In Acquisitions

Glooko will use the proceeds to expand into new geographies and take advantage of rising reimbursement for digital health, expand solutions for co-morbid conditions, and explore tuck-in acquisitions.

Telehealth Digital Health

Market Intel: Rivalry Among Insulin Pump Makers Heats Up With Expected Launches In 2021

The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021. 

Market Intelligence Diabetic Care
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Insulet Canada Corporation
    • Neighborhood Diabetes
    • Neighborhood Holdings, Inc.
UsernamePublicRestriction

Register